MedTrace Logo

An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement

NCT02293681 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2017-11-01

No results posted yet for this study

Summary

The purpose of this observational (a study that follows participants forward in time) study is to compare the functional improvement of hip joint using Harris hip score between 2 treatment groups (infliximab and conventional therapy) at Week 30 in ankylosing spondylitis (an autoimmune disease causing chronic inflammation at tendon ends and ligament attachment points) participants with hip involvement.

Conditions

  • Spondylitis, Ankylosing

Interventions

DRUG

Infliximab

This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.

DRUG

NSAIDs

This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.

DRUG

DMARDs

This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-10
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02293681 on ClinicalTrials.gov